BGLC Company Profile and Key Details

BGLC has shown weak momentum, losing -11.73% over the past week and -35.48% over the past quarter, though year-to-date performance is down -16.2%. Short-term trend indicators are bullishly aligned (SMA20 7.55%, SMA50 -21.53%, SMA200 -42.82%). The stock’s 14-day RSI is 45.11 (neutral), while the ATR of 0.18 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -83.97% below its high and over 30.21% above its low. Average 10-day trading volume of 6.05 thousand shares is below the 3-month average of 99.71 thousand, indicating normal recent market interest.

BioNexus Gene Lab Corp. generated EPS of -$1.28 over the past year. Five-year average earnings growth is -21.27%.

BioNexus Gene Lab Corp. has 2.42 million shares outstanding. The public float is 1.76 million shares, elevated short interest at 1.10% of float. This equals 22.28 thousand shares. The short ratio is 0.81 days. Institutional investors hold 1.09% of the float. Insiders own 51.11%.

BioNexus Gene Lab Corp. (NASDAQ:BGLC) closed at $1.64 USD, losing -$0.10 (-5.75%) from the previous close of $1.74. The stock is currently mid-range between its 52-week high and low $1.07 and $8.98. With a market capitalization of about $3.30 million, BioNexus Gene Lab Corp. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.21). Key stats such as the average daily volume over the past year has been around 100.67 thousand shares, volume is running light vs its 52-week average. Headquartered in Kuala Lumpur, WP, BioNexus Gene Lab Corp. operates in the Industrials sector and the Industrial - Distribution industry. Led by CEO Su-Leng Tan, the company employs approximately 19 people and listed since January 08, 2021. BioNexus Gene Lab Corp. (BGLC), established in 2017 and headquartered in Kuala Lumpur, Malaysia, conducts business through two primary subsidiaries.

BioNexus Gene Lab Corp. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$8.03. This means the shares are trading below this model’s fair value.

BioNexus Gene Lab Corp. trades at a P/E ratio of -1.08, slightly below the S&P 500 average, with a price-to-sales ratio of 0.61 and a price-to-book ratio of 0.48 suggesting the stock is closer to book value. The P/FCF stands at -2.72, also below market averages.

Our AI price prediction model suggests that BioNexus Gene Lab Corp. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.83%, with price expected at $1.61 by July 27, 2026, within a range of $1.41 to $1.80 3-Month Outlook: Projected rise of 171.34%, reaching $4.45 by October 09, 2026, with a range of $3.90 to $4.79. 1-Year Outlook: Projected gain of 16.46%, with price at $1.91 by July 13, 2027, within a range of $0.00 to $3.59.

BioNexus Gene Lab Corp. (NASDAQ:BGLC) shares are down -16.2% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows BioNexus Gene Lab Corp. trading at a premium to the broader market with a P/E of -1.08. Our AI forecast model points to short-term weakness (-1.83% over two weeks), a medium-term rise (171.34% over three months), and a longer-term gain (16.46% over one year), with expected trading ranges indicating moderate volatility.